by Clinical Neuropsychologist | Monday, June 17, 2024 | Neurology
Background An oral sodium phenylbutyrate and taurursodiol combination (PB and TURSO) significantly reduced functional decline in people living with amyotrophic lateral sclerosis (ALS) in the CENTAUR trial. Biomarkers linking clinical therapeutic effect with biological...
by Clinical Neuropsychologist | Monday, June 17, 2024 | Neurology
Background Objective disease activity biomarkers are lacking in chronic inflammatory demyelinating polyneuropathy (CIDP), impacting treatment decisions in clinical care and outcomes in clinical trials. Using a proximity extension assay, we aimed to identify candidate...
by Clinical Neuropsychologist | Monday, June 17, 2024 | Neurology
Several disease-modifying treatments increase seizure risk in multiple sclerosis and meta-analyses of randomised trials do not really disagree on this In their JNNP meta-analysis Pozzilli et al concludes that sphingosine-1-phosphate receptor (S1PR) modulators...
by Clinical Neuropsychologist | Friday, June 14, 2024 | Neurology
Purpose of review There is no diagnostic biomarker that can reliably detect Guillain–Barré syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP). Diagnosis relies upon integrating key clinical characteristics and relevant supportive data....
by Clinical Neuropsychologist | Friday, June 14, 2024 | Neurology
Purpose of review Charcot-Marie-Tooth (CMT) neuropathies are rare, genetically heterogeneous and progressive diseases for which there are no approved treatments and their management remains mostly supportive and symptomatic. This review is intended to provide an...
by Clinical Neuropsychologist | Wednesday, June 12, 2024 | Neurology
Purpose of review To examine the evidence evaluating the association between obesity and neuropathy as well as potential interventions. Recent findings Although diabetes has long been associated with neuropathy, additional metabolic syndrome components, including...
